CROI 2015 Program and Abstracts

Poster Listings

979 Correlates of Early Adherence in VOICE PrEP Trial Differ Between Oral and Vaginal Products Ariane van der Straten 1 ; Elizabeth R. Brown 2 ; James Dai 2 ; Craig Hendrix 3 ; Karen Liu 2 ; Cynthia Grossman 4 ; Z M. Chirenje 5 ; Jeanne Marrazzo 6 1 RTI, San Francisco, CA, US; 2 Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US; 3 Johns Hopkins University School of Medicine, Baltimore, MD, US; 4 National Institute of Mental Health (NIMH), Bethesda, MD, US; 5 University of Zimbabwe–University of California San Francisco Research Collaboration, Harare, Zimbabwe; 6 University of Washington, Seattle, WA, US 980 Intimate Partner Violence Is AssociatedWith Low PrEP Adherence in AfricanWomen Sarah T. Roberts 1 ; Connie Celum 1 ; Nelly Mugo 3 ; Jessica Haberer 2 ; Craig R. Cohen 4 ; Elizabeth Irungu 5 ; James N. Kiarie 6 ; EdwinWere 7 ; Jared Baeten 1 On behalf of the Partners PrEP StudyTeam 1 University of Washington, Seattle, WA, US; 2 Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 3 Kenya Medical Research Institute, Nairobi, Kenya; 4 University of California San Francisco, San Francisco, CA, US; 5 Kenyatta National Hospital, Nairobi, Kenya; 6 University of Nairobi, Nairobi, Kenya; 7 Moi University, Eldoret, Kenya 2:30 pm– 4:00 pm PrEP: Evaluating Potential Harm 981 Reversibility of Kidney Function Decline in HIV-1 – Uninfected Men and Women Using Preexposure Prophylaxis Kenneth K. Mugwanya 1 ; ChristinaWyatt 2 ; Connie Celum 1 ; Deborah Donnell 3 ; Nelly Mugo 4 ; 1 University of Washington, Seattle, WA, US; 2 Mount Sinai School of Medicine, New York, NY, US; 3 Fred Hutchinson Cancer Research Center, Seattle, WA, US; 4 Kenya Medical Research Institute, Nairobi, Kenya; 5 University of Nairobi, Nairobi, Kenya; 6 University of Manitoba, Winnipeg, Canada 982 Minor Drug-Resistant Variants Infrequently Detected in Seroconverters FromMTN 003 (VOICE) Constantinos Panousis 1 ; Elias K. Halvas 1 ; Cliff Kelly 2 ; Jeanne Marrazzo 3 ; Z M. Chirenje 4 ; John W. Mellors 1 ; Urvi M. Parikh 1 On behalf of the MTN 003 ProtocolTeam 1 University of Pittsburgh, Pittsburgh, PA, US; 2 Fred Hutchinson Cancer Research Center, Seattle, WA, US; 3 University of Washington, Seattle, WA, US; 4 UZ-UCSF Collaborative Research Programme, Harare, Zimbabwe 983 PrEP-Selected Drug Resistance Fades by Six Months Following Drug Cessation Julie F. Weis 1 ; Jared Baeten 2 ; Ruth Kanthula 3 ; Connor McCoy 1 ; Lisa Frenkel 2 ; Nelly Mugo 2 ; Frederick Matsen 1 ; Julie M. Overbaugh 1 ; Connie Celum 2 ; Dara A. Lehman 1 1 Fred Hutchinson Cancer Research Center, Seattle, WA, US; 2 University of Washington, Seattle, WA, US; 3 Seattle Children’s Research Institute, Seattle, WA, US; 4 Fred Hutchinson Cancer Research Center, Seattle, WA, US 984 Randomized Controlled Trial on ART Outcomes in Tenofovir Gel Trial Seroconvertors Anushka Naidoo ; Nivashnee Naicker; LiseWerner; Nigel Garrett; Sarah Dlamini;Villeshni Asari; Nelisile Majola; Cheryl Baxter; Quarraisha Abdool Karim; Salim S. Abdool Karim Center for the AIDS Program of Research in South Africa, Durban, South Africa 985 Frequent Dapivirine Cross-Resistance of HIV from 1 st -line ART Failures in S. Africa Kerri J. Penrose 1 ; Kristen A. Hamanishi 1 ; Kelley C. Gordon 1 ; RaquelV.Viana 2 ; Carole L. Wallis 3 ; JohnW. Mellors 1 ; Urvi M. Parikh 1 1 University of Pittsburgh, Pittsburgh, PA, US; 2 Lancet Laboratories, Johannesburg, South Africa; 3 Lancet Laboratories/BARC-SA, Johannesburg, South Africa James N. Kiarie 5 ; Allan Ronald 6 ; Jared Baeten 1 On behalf of the Partners PrEP StudyTeam WEDNESDAY, FEBRUARY 25, 2015 Session P-V5 Poster Session Poster Hall

986 Effect of TDF Monotherapy PrEP on Immune Function in Seroconverting Individuals Marcel E. Curlin 1 ; MichaelT. Martin 1 ; PunneepornWasinrapee 2 ;Wanna Leelawiwat 2 ; Boonyos Raengsakulrach 2 ; Janet McNicholl 1 ; Pravan Suntharasamai 3 ; Udomsak Sangkum 3 ; SuphakVanichseni 3 ; Kachit Choopanya 3 1 US Centers for Disease Control and Prevention (CDC), Apo, US; 2 Thailand Ministry of Public Health-Centers for Disease Control and Prevention Collaboration, Nothaburi, Thailand; 3 Bangkok Tenofovir Study Group, Bangkok, Thailand 987 The Impact of Preexposure Prophylaxis on Antibody Maturation in HIV- InfectedWomen Oliver B. Laeyendecker 1 ; Andrew D. Redd 1 ; Martha Nason 3 ; Andrew Longosz 1 ; Quarraisha Abdool Karim 2 ;Vivek Naranbhai 2 ; Nigel Garrett 2 ; Salim S. Abdool Karim 2 ;Thomas C. Quinn 1 1 National Institute of Allergy and Infectious Diseases, Baltimore, MD, US; 2 CAPRISA, University of KwaZulu-Natal, Congella, South Africa; 3 National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, US 988 Medication Sharing Among African HIV Serodiscordant Couples Enrolled in a PrEP Trial Kerry A. Thomson 1 ; Jessica Haberer 4 ; Connie Celum 1 ; Andrew Mujugira 1 ; Patrick Ndase 1 ; Craig Hendrix 2 ; Mark A. Marzinke 2 ; Allan Ronald 3 ; David Bangsberg 4 ; Jared Baeten 1 On behalf of the Partners PrEP StudyTeam 1 University of Washington, Seattle, MA, US; 2 Johns Hopkins University, Baltimore, MD, US; 3 University of Manitoba, Winnipeg, Canada; 4 Massachusetts General Hospital, Boston, MA, US AndrewMujugira 1 ; KatherineThomas 1 ; Connie Celum 1 ; Deborah Donnell 2 ; Carey Farquhar 1 ; Elizabeth Bukusi 3 ; Jared Baeten 1 On behalf of the Partners PrEP StudyTeam 1 University of Washington, Seattle, WA, US; 2 Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US; 3 Kenya Medical Research Institute, Nairobi, Kenya 990 Long-Term ART Outcomes in Botswana Encouraging Treatment as Prevention Approach Hermann Bussmann 4 ;William C.Wester 1 ; Ernest Fetogang 2 ;Tony Chebani 2 ; Sikhulile Moyo 3 ; Naledi M. Mlaudzi 2 ; ErikV.Widenfelt 3 ; Joseph Makhema 3 ; Max Essex 4 ; Richard Marlink 4 1 Vanderbilt University School of Medicine, Nahville, TN, US; 2 Ministry of Health, Gaborone, Botswana; 3 Botswana Harvard AIDS Institute Partnership for HIV Research and Education, Gaborone, Botswana; 4 Harvard School of Public Health, Boston, MA, US 991LB Use of Population Viral Load to Predict HIV-Incidence in a Hyperendemic Population in Rural KwaZulu-Natal, South Africa Frank Tanser 3 ;Tulio de Oliveira 3 ;Till Barnighausen 2 ; Deenan Pillay 1 1 University College London, London, United Kingdom; 2 Harvard School of Public Health, Boston, MA, US; 3 University of KwaZulu-Natal, Mtubatuba, South Africa 992LB Phase 1 Safety & PK Trial of Polyurethane Tenofovir Disoproxil Fumarate Vaginal Ring Marla J. Keller 1 ; Pedro Mesquita 1 ; Mark A. Marzinke 2 ; RyanTeller 3 ; Bruce Frank 4 ; Mark Mitchnick 4 ; Peter L. Anderson 5 ; Craig Hendrix 2 ; Patrick F. Kiser 3 ; Betsy Herold 1 1 Albert Einstein College of Medicine, Bronx, NY, US; 2 Johns Hopkins University School of Medicine, Baltimore, MD, US; 3 Northwestern University, Evanston, IL, US; 4 Particle Sciences, Inc, Bethlehem, PA, US; 5 University of Colorado, Aurora, CO, US 993 Investigating the Pharmacokinetics of Rectal 1% Tenofovir Gel in Rhesus Macaques Charles W. Dobard 1 ; AndrewTaylor 1 ; Chuong Dinh 1 ; Chou-Pong Pau 1 ; Ian McGowan 2 ; Lisa Rohan 2 ;Walid Heneine 1 1 Centers for Disease Control and Prevention, Atlanta, GA, USA, Atlanta, GA, US; 2 University of Pittsburgh Magee-Womens Research Institute, Pittsburgh, PA, US THURSDAY, FEBRUARY 26, 2015 Session P-V6 Poster Session Poster Hall 2:30 pm– 4:00 pm HIV Prevention, Miscellaneous 989 HIV-1 Transmission Risk Persists During the First 6 Months of Antiretroviral Therapy

Poster Listings

75

CROI 2015